Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
종목 코드 MRKR
회사 이름Marker Therapeutics Inc
상장일Nov 08, 2016
설립일2018
CEODr. Juan F. Vera, M.D.
직원 수5
유형Ordinary Share
회계 연도 종료Nov 08
주소2450 Holcombe Blvd
도시HOUSTON
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호77021
전화17134006400
웹사이트https://markertherapeutics.com/
종목 코드 MRKR
상장일Nov 08, 2016
설립일2018
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음